BenevolentAI Investor Presentation Deck

I Leveraging Al to increase efficiency of the drug discovery process Research Biology Target Identification Hyp Gen Hyp Val Hit ID & Expansion Chemistry Discovery Lead Op Candidate Seeking Preclinical Deployment Development Phase I Up to $2.6bn and c.10 years with a high probability of failure Phase II Phase III Approval & Launch 96% Failure Al already is, or will have, an impact over each segment of the Drug Development continuum, empowering scientists to make better decisions, quicker with clear financial benefits Benevolent

View entire presentation